Lineage Cell Therapeutics, Inc. (LCTX) Covered Calls

You can sell covered calls on Lineage Cell Therapeutics, Inc. to lower risk and earn monthly income. Born To Sell's covered call screener gives you customized search capabilities across all possible covered calls but here are a couple of examples for LCTX (prices last updated Fri 4:16 PM ET):

Lineage Cell Therapeutics, Inc. (LCTX) Stock Quote
Last Change Bid Ask Volume P/E Market Cap
0.86 -0.02 0.85 0.88 874K - 0.2
Covered Calls For Lineage Cell Therapeutics, Inc. (LCTX)
Expiration Strike Call Bid Net Debit Return
If Flat
Annualized
Return If Flat
Dec 20 2.5 0.00 0.88 0.0% 0.0%
Jan 17 2.5 0.00 0.88 0.0% 0.0%
Subscribers get access to the full covered call chain, and more features.

Want to make money with covered calls?  Sign Up For A Free Trial


Extended Business Description

Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing therapies for the treatment of degenerative diseases in the United States and internationally. The company's lead product candidates include OpRegen, a retinal pigment epithelium cell replacement therapy, which is in Phase I/IIa clinical trial for the treatment of the dry age-related macular degeneration; OPC1, an oligodendrocyte progenitor cell therapy that is in Phase I/IIa multicenter clinical trial for the treatment of acute spinal cord injuries; and VAC2, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells, which is in Phase I clinical trial to treat non-small cell lung cancer. It also develops Renevia, a facial aesthetics product that is in clinical trial for the treatment of HIV-associated facial lipoatrophy; HyStem, a biomaterial used for cell replacement and retention; and Premvia, a Hystem Hydrogel product, as well as develops bone grafting products for the orthopedic diseases and injuries. In addition, the company offers various therapeutic products for the treatment of oncology, neurological diseases and disorders, blood and vascular system diseases and disorders, and blood plasma volume expansion, as well as undertakes various research programs for vision restoration and Demyelination. Lineage Cell Therapeutics, Inc. has a collaboration with Orbit Biomedical, Ltd. The company was formerly known as BioTime, Inc. and changed its name to Lineage Cell Therapeutics, Inc. in August 2019. Lineage Cell Therapeutics, Inc. was founded in 1990 and is headquartered in Carlsbad, California.